Omg, this could literally make ANYONE do CR at last?
DEFINE_ME you only need ONE dose per week
3 Likes
This should be tested in the ITP program! Very interesting.
Seems like its just being launched or will be soon if phase 3 trials are successful, but it will likely be expensive, as a new, patented drug.
The phase 1b and phase 2 clinical trials have only recently been completed:
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00845-X/fulltext
and
Promising phase 2 results for long-acting amylin analog cagrilintide
2 Likes
It’s widely available on various peptide sites now
At 32 weeks, patients treated with once-weekly injections of CagriSema had an HbA1c reduction of 2.2% compared with reductions of 1.8% with semaglutide alone and 0.9% with cagrilintide alone, reported Juan Frías, MD, of Velocity Clinical Research in Los Angeles, during the American Diabetes Association (ADA) Scientific …Jun 27, 2023
it’s more expensive than semaglutide though it synergizes. still, for most people semaglutide should be good enough
1 Like
Neo
#5
They should something in this broader family, but issues in the past has been needs to be pill/food based and not subcutaneous injections 
1 Like
Neo
#6
Any sense of this increased baseline insulin levels, that’s my worry with GLP-1 as CR mimetic that key longevity pathway (and IGF, etc) might actually go in the wrong direction with these
2.2% is quite a large A1C reduction (although the sample size was not that big). I can see this as an attractive options for diabetics with very high blood sugar especially is this is approved before retatrutide and some of the other new drugs in development.
It is nice to see new drugs being developed with different pathways (or used in combination like CagriSema) so we can better compare/contrast them when used alone or in combination with each other.
Davin8r
#8
Fasting insulin went down dose-dependently in the retatrutide phase 2 study, for instance (see Table S6):
https://www.nejm.org/doi/suppl/10.1056/NEJMoa2301972/suppl_file/nejmoa2301972_appendix.pdf
I haven’t looked at sema or tirz data specifically, but I’d imagine it’s the same. I believe the increased insulin output only happens postprandially (i.e. after a meal) and not round-the-clock.
Neo
#9
Thanks David. Key question though, are these overweight, generally unhealthy and not metabolically flexible and fit individuals?
My question is what the effect is on generally healthy, lean, metabolically flexible and fit longevity optimizers.
The effects in the first group could be net decrease in insulin (and the direct GLP-1 => higher insulin effect is offset by less food and more metabolic health) without saying what or if the opposite would occur in the second, health optimizing group.
Someone told me CagriSema prevents muscle wasting seom semaglutide? but I cant find sources
